New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:00 EDTFURX, SLXPFurex drug should not be seen as threat to Salix, says Piper Jaffray
Piper Jaffray believes Furiex's (FURX) receptor antagonist eluxadoline in diarrhea-predominant irritable bowel syndrome should not be seen as a threat to Salix's (SLXP) Xifaxan in IBS-D. Piper says eluxdaoline and Xifaxan are mechanistically very different and will be used differently. The firm views Salix as attractive and reiterates an Overweight rating on the stock with a $106 price target.
News For SLXP;FURX From The Last 14 Days
Check below for free stories on SLXP;FURX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
17:32 EDTSLXPSalix announces tentative FDA approval of UCERIS rectal foam
Subscribe for More Information
15:55 EDTSLXPSalix price target raised to $172 from $163 at Buckingham
Subscribe for More Information
15:41 EDTSLXPSalix calls active on takeover chatter
Subscribe for More Information
07:47 EDTSLXPFDA PDUFA Date for Salix Pharmaceuticals Budesonide is September 15, 2014
September 12, 2014
10:00 EDTSLXPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:06 EDTSLXPFollow-up: Salix initiated with an Underperform at Credit Suisse
Subscribe for More Information
06:41 EDTSLXPSalix initiated with an Underperform at Credit Suisse
Subscribe for More Information
September 8, 2014
07:21 EDTSLXPJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 2, 2014
07:21 EDTSLXPSalix submits response to FDA's CRL regarding XIFAXAN 550 mg tablets sNDA
Salix Pharmaceuticals announced that on August 29, it submitted its response to the March 7, 2011, FDA Complete Response Letter, or CRL, regarding the Company’s supplemental New Drug Application, or sNDA, for XIFAXAN 550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D. Upon receipt of Salix’s response, the FDA will have six months to issue a response.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use